406 SODIUM MRI OF ARTICULAR CARTILAGE AFTER ANTERIOR CRUCIATE LIGAMENT INJURY  by Gold, G. et al.
S214 Poster Presentations
1, 7 (3.5%) grade 2 and no grade 3 lesions were observed. 93
(46.5%) BMLs that were seen on the IW TSE FS were not de-
tectable on the DESS. Assessment of BML size was superior for
the sagittal IW TSE FS sequence (P<0.001). 113 cystic lesions
were observed. No signiﬁcant difference was found for differenti-
ation between non-cystic and cystic part of BMLs. In 89 (78.8%)
cases the DESS delineated the cystic lesions superiorly. No differ-
ence between the sequences was seen in 24 (21.2%) cases. The
DESS sequence showed superiority for cyst delineation (p<0.001).
Conclusions: Full extent of non-cystic BMLs is only shown on the
IW TSE FS sequence. The DESS sequence helps in the differ-
entiation of non-cystic vs. cystic parts of BMLs as it depicted the
cyst delineation superiorly. Both sequences are complementary,
but size of BMLs should only be assessed on the IW TSE FS
sequence.
Semiquantitative assessment of non-cystic subchondral bone mar-
row lesions should be performed on sequences that depict these
lesions to their maximum extent.
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Purpose: The absence of a proxy biomarker for measurement of
structural progression of knee OA has been a major impediment to
development of disease-modifying interventions for this common,
disabling disorder. Several novel technological approaches have
emerged with the potential to measure changes in articular carti-
lage. Two of these include T1-mapping of cartilage after contrast
administration (delayed Gadolinium Enhanced MRI of Cartilage,
dGEMRIC) and T2-mapping.
We performed a pilot study to test ability of these parameters
to detect changes in cartilage characteristics in human knee OA
following a 24-week course of oral proprietary collagen hydrolysate
Fortigel®. This is a nutritional product produced by GELITA shown
to have anabolic effects on chondrocytes in-vivo and reduce
progression of OA in animal models.
Methods: We performed a randomized, placebo-controlled,
double-blind, 24-week clinical trial of 10 grams collagen hy-
drolysate orally once per day among 30 participants with symp-
tomatic knee OA. There was a planned option for a further 24-week
extension of the clinical trial based on a blinded assessment (A
vs. B) of the 24-week data by the study Data & Safety Monitoring
Board. Fortigel® and placebo formulations were indistinguishable
in appearance and ﬂavor. Treatment assignment was according
to a blocked randomization scheme, stratiﬁed by body mass in-
dex (BMI). We permitted participants to take acetaminophen or
non-steroidal anti-inﬂammatory drugs at their regular dose and
tramadol for breakthrough pain. Participants received clinical as-
sessment every 8 weeks and dGEMRIC and T2 MRI scans at
baseline, 24 and 48 weeks. dGEMRIC index and T2 values were
calculated in 6 speciﬁed regions of interest in cartilage. The
primary outcome was change in dGEMRIC index in the study
knee hyaline cartilage. Secondary endpoints included change in
cartilage mean T2 relaxation time, WOMAC scores, timed walk
and chair stand tests. We tested for differences between groups
using a Wilcoxon Rank Sum (non-parametric) test since there
was evidence of a non-normality of distribution of study out-
comes.
Results: The assignment groups were balanced in most respects
but the placebo group had slightly more functional limitation (table
1). The DSMB recommended continuation for the full 48 weeks.
During the ﬁrst 24 weeks, the dGEMRIC indices in the medial
and lateral tibial regions fell in the placebo group but increased in
the treatment group (table 2). Signiﬁcant trends were not seen for
other regions of interest or T2 values. The clinical indices broadly
improved in both groups without any major differences between
them (e.g. change in WOMAC pain at 24 weeks: -1.4 versus
-1.5, p=ns). Analysis of the 48-week outcomes showed no further
change.
Table 1. Demographics and baseline characteristics of participants
Placebo (n=15) CH (n=15)
Age, y, mean (SD) 60.3 (8.5) 58.9 (8.0)
Gender, female, n (%) 9 (60%) 9 (60%)
Race, white, n (%) 13 (87%) 14 (93%)
BMI, kg/m2, mean (SD) 31.1 (7.2) 29.9 (4.6)
KL score = 2, n (%) 13 (87%) 14 (93%)
dGEMRIC Index, msec (SD)
Medial Tibia 408 (80) 366 (81)
Central Medial Femur 413 (80) 421 (56)
Posterior Medial Femur 425 (74) 435 (62)
Lateral Tibia 450 (89) 426 (89)
Central Lateral Femur 414 (76) 430 (67)
Posterior Lateral Femur 400 (52) 414 (83)
WOMAC (SD)
Pain 5.8 (3.0) 4.6 (2.6)
Stiffness 2.8 (1.5) 2.9 (1.1)
Function 20.6 (10.9) 12.9 (8.7)*
Total 29.2 (13.9) 20.3 (10.5)
20-meter walk, median, sec 17.9 16.2
Chair stand, sec (SD) 17.7 (5.9) 14.7 (3.5)
Table 2. Median Change in dGEMRIC Index from Baseline to 24 and 48 weeks
Placebo Group CH Group
0-24 weeks 0-48 weeks 0-24 weeks 0-48 weeks
Medial Tibia -38.0 14.0 28.0* 47.0
Lateral Tibia -33.5 -1.0 40.0* 28.0
Central Medial Femur 21.0 -5.0 -18.0 17.0
Posterior Medial Femur 22.5 -6.0 26.0 15.0
Central Lateral Femur 26.0 2.0 -17.0 -6.0
Posterior Lateral Femur 30.5 19.0 36.0 32.0
*Between group p-value <0.05.
Conclusions: In summary, the dGEMRIC index was able to dis-
criminate between treatment and placebo groups in the tibial
regions. The directionality of this change is compatible with an
increase in proteoglycan content of hyaline cartilage in those re-
ceiving Fortigel® and a decrease among those on the placebo.
The sample size was small, so these data should be regarded as
preliminary.
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Purpose: Early degenerative changes in articular cartilage leading
to osteoarthritis are accompanied by glycosaminoglycan (GAG)
depletion in the cartilage matrix. Subjects with prior tears to the
anterior cruciate ligament (ACL) may show early development
of osteoarthritis. Sodium MRI has been shown to correlate with
GAG concentration, and may be useful in detecting and tracking
early GAG depletion. Sodium MRI is challenging due to relatively
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low sodium concentrations in biological tissues, and rapid signal
decay. Despite these challenges, improved hardware coupled with
higher ﬁeld strengths enable diagnostic-quality sodium MRI in vivo
in reasonable scan times. Short-TE gradient-spoiled sequences
with efﬁcient k-space trajectories are often employed to maximize
sodium signal and minimize blurring from signal decay.
Methods: Thirty-four knees of 17 subjects with previous unilateral
ACL tears were imaged in the sagittal plane using a GE Signa
Exite 3.0T MRI scanner and custom quadrature sodium knee coil.
Both the injured knee and uninjured knees were scanned. We
studied 8 male and 9 female patients (age 21-47) with a range of
2-13 years after ACL injury.
A fast gradient-spoiled sequence using the 3D cones k-space
trajectory and a rapid excitation was developed for sodium image
acquisition. Imaging parameters were TR/TE 35/0.6 ms, ﬂip angle
70 degrees, 28 signal averages. Resolution of the sodium MRI ac-
quisition was 1.25×1.25×4 mm with a 21 minute imaging time. B1
maps obtained using a dual-ﬂip angle approach in vivo conﬁrmed
a ﬂip angle variation of less than 5% across the ﬁeld of view of
the coil. A 100-mmol-concentration test tube of saline was placed
within the coil to normalize for signal differences between scans.
Conventional proton imaging with a 3D fat-suppressed spoiled
gradient echo scan was done to look for cartilage loss. The move-
ment of the subject was minimized between sodium and proton
scans to facilitate registration.
For each subject, the signal of the sodium in the images was
measured using regions of interest in the central regions of the
medial and lateral femoral and tibial cartilage with OSIRIX. Signal
was normalized by the image noise and signal from the test tube.
Normalized sodium signal was regressed on knee status (normal
or surgery) and cartilage region (femur/tibia and medial/lateral),
using a PA-GEE regression.
Results: None of the 17 subjects studied showed areas of full
thickness cartilage loss on the proton MRI images. Knees with
ACL injury had signiﬁcantly lower sodium signal levels (19.6 vs.
22.7, p <0.001). Medial regions had signiﬁcantly higher sodium
signal levels than lateral ones (21.6 vs. 20.7, p <0.008). Within-
patient correlation was 0.83. Without exception, signal levels were
lower in all regions from knees with ACL injury when compared
to corresponding regions in the same patient’s intact knee. A
representative image is shown in the ﬁgure, with normal appearing
cartilage on the proton image, and area of GAG depletion on the
sodium image (arrows).
Conclusions: Our results show that whole knee sodium MRI
at 3.0T can detect early changes in articular cartilage sodium
signal for patients with previous ACL tears. Sodium signal from
articular cartilage has been shown to correlate directly with GAG
content. In vivo sodium MRI is promising for detection of GAG
depletion that may occur prior to cartilage loss in osteoarthritis.
The ability to non-invasively quantify GAG loss may help with
treatment development and rehabilitation of ACL injury.
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Purpose: Cross sectional studies have indicated that knees with
early radiographic change displayed increased cartilage thickness
in MRI versus healthy knees. A natural history trial recently re-
ported that only 25% of the knees with symptomatic radiographic
OA showed signiﬁcant cartilage thinning over 2 years in at least
one medial femorotibial subregion compared with a healthy refer-
ence cohort, whereas 15% displayed signiﬁcant cartilage thicken-
ing and 60% no signiﬁcant change in thickness. When evaluating
whether a DMOAD can prevent cartilage thinning (loss) it is impor-
tant to predict which knees will change and which ones will not.
The objective was thus to identify speciﬁc predictors of cartilage
thinning and thickening in OA knees.
Methods: One knee in each of 152 female participants was fol-
lowed over 2 years at 7 clinical centers using 3T MR imaging (1.0
mm coronal FLASHwe). 77 knees had no symptoms and no evi-
dence of radiographic OA in either AP or Lyon Schuss radiographs,
whereas 75 displayed signs of medial femorotibial radiographic OA
in at least one radiograph and a range of symptoms. Cartilage
thickness (ThC) was determined in 8 subregions (5 medial tibial,
MT; 3 medial femoral, cMF) in baseline and follow up images using
custom software (Chondrometrics GmbH, Ainring, Germany). OA
participants with signiﬁcant longitudinal cartilage thinning, thick-
ening or no change in any of the 8 subregions were identiﬁed
based on comparison to the z-distribution of change in the healthy
reference knees. Receiver Operator Characteristic (ROC) analysis
and Mann Whitney tests were used to determine which baseline
measures discriminated between subcohorts. These measures in-
cluded clinical and radiographic status, cartilage morphology and
composition, meniscus status (subluxation, height and coverage),
and biochemical biomarkers from the urine normalized to crea-
tinine (u), plasma (p), or serum (s), i.e. uOsteopontin, uTINEr,
uTIINE, uTIIINE, uAgg, pPGE2, p15HETE, pNPII, pYNO2, sPI-
IANP, sIntactPINP, sCOMP, sCPII, sPIIINP, uCTXII.
Results: 19 of 75 OA knees showed signiﬁcant cartilage thin-
Table 1. Area under the curve values (AUC from ROC analysis) and signiﬁcance
levels (Mann Whitney)
Thinning vs. Thinning vs. Thickening vs. Thickening vs.
no thinning no change no change thinning
BMI 0.59 0.62 0.64 0.50
WOMAC pain 0.60 0.63 0.69 0.57
WOMAC stiffness 0.67* (+) 0.68* (+) 0.57 0.64
WOMAC function 0.65 0.68* (+) 0.69* (+) 0.53
JSN (Lyon Schuss) 0.74** (–) 0.74** (–) 0.51 0.76* (+)
Knee alignment 0.75**§ 0.77**§ 0.55 0.68
ThC MT (MRI) 0.56 0.57 0.55 0.56
ThC cMF (MRI) 0.79*** (–) 0.81*** (–) 0.59 0.76* (+)
Meniscus morphology up to 0.61 up to 0.63 up to 0.59 up to 0.60
Mean dGEMRIC MFTC 0.64 0.66* (–) 0.61 0.60
Mean T2 MFTC 0.55 0.48 0.60 0.69
SD T2 MFTC 0.63 0.66* (–) 0.78** (-) 0.65
sCTXI 0.66* (-) 0.65* (–) 0.50 0.68
Other biochem markers up to 0.62 up to 0.64 up to 0.68 up to 0.73
*p<0.05, **p<0.01,***p<0.001; (+) = reater value and (–) = lower value in ﬁrst
group; §stronger varus malalignment, MT = medial tibia, cMF = medial femur;
MFTC = medial femorotibial compartment [= MT+cMF]).
